Welcome to our dedicated page for Adlai Nortye Ltd. SEC filings (Ticker: ANL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adlai Nortye Ltd. filings document foreign private issuer reports for a clinical-stage oncology biotechnology company whose securities trade as American depositary shares. The company’s Form 6-K reports include pipeline disclosures for AN9025, AN4035, AN8025, AN4005 and AN0025; clinical and regulatory updates; unaudited financial results; corporate presentations; and material agreements.
ANL filings also record capital-structure matters, including private-placement securities purchase agreements and ADS-to-Class A ordinary share references, as well as shareholder meeting materials, proxy cards, board and committee changes, executive appointments, and the adoption of a share incentive plan.
Adlai Nortye Ltd. announced several leadership changes effective April 1, 2026. Archie Tse, M.D., Ph.D., was appointed President while continuing as Head of Research and Development, a role he has held since March 2024. His background includes senior R&D positions at multinational pharmaceutical companies.
The Board also appointed Dr. Ye as Chief Financial Officer, in addition to his responsibilities for business development and global commercialization strategy, after serving as interim CFO since January 2025. He brings experience in business development and commercial leadership across the Asia-Pacific region.
Current President Dr. Kaiyang Tang retired from the president role on April 1, 2026 and will remain as a Corporate Strategy Professor to support a smooth transition. The company states his retirement does not affect operations in finance, investor relations, or public relations, and that he has no disputes or disagreements with the company.
Adlai Nortye Ltd. filed a Form F-3 shelf registration to offer up to US$600,000,000 of Class A ordinary shares and to register for resale up to 64,615,386 Class A ordinary shares (represented by 21,538,462 ADSs), from time to time after the effective date. The prospectus states the selling shareholders’ sales will provide no proceeds to the company, and that ADSs trade on Nasdaq under the symbol ANL. The prospectus describes the securities, dual-class share structure, risk factors including HFCAA-related delisting risk, and that specific offering terms will be provided in prospectus supplements.
Adlai Nortye Ltd. reported that the first patient has been dosed in a global Phase 1 clinical trial of AN9025, its oral pan-RAS(ON) inhibitor for advanced or metastatic solid tumors with RAS mutations. This first-in-human, multicenter, open-label study will assess safety, tolerability, pharmacokinetics and early anti-tumor activity.
The trial is being run as a multi-regional clinical trial in collaboration with ASK Pharm, with Adlai Nortye holding rights to AN9025 outside mainland China, Hong Kong and Macao. AN9025 is part of the company’s broader oncology pipeline, which also includes next-generation cancer immunotherapies and additional RAS-targeting candidates.
Venrock-affiliated investment funds and two principals report a passive 6.1% ownership stake in Adlai Nortye Ltd. They beneficially own 9,638,193 ordinary shares, held through American Depositary Shares, each representing three ordinary shares.
The stake is spread across three Venrock Healthcare Capital vehicles, with governance handled by Delaware management entities linked to Nimish Shah and Bong Y. Koh. The ownership percentage is calculated against 93,710,803 ordinary shares outstanding as of June 30, 2025, plus 64,615,386 ordinary shares issued in a February 4, 2026 private placement. The group certifies the shares are not held to change or influence control of Adlai Nortye.
Adlai Nortye Ltd. saw a major institutional holder file an amended ownership report showing it no longer owns any of the company’s American Depositary Shares. Unique Mark Ventures Limited and its parent Fine Process Limited each report beneficial ownership of 0.00 shares, or 0.00% of the class.
The filing explains that Unique Mark Ventures, wholly owned by Fine Process and ultimately linked to ICBC group entities, has disposed of all its shares and ceased to be a shareholder as of this amendment. All voting and dispositive power figures in the report are listed as zero.
Adlai Nortye Ltd. entered into securities purchase agreements for a private placement equity financing expected to raise approximately $140.0 million in gross proceeds, before fees and expenses. The company is selling 64,615,386 Class A ordinary shares, equivalent to 21,538,462 ADSs, at $2.1667 per ordinary share (or $6.50 per ADS).
The private placement, co-led by Cormorant Asset Management and Columbia Threadneedle Investments with several other institutional investors, is expected to close on February 4, 2026, subject to customary conditions. Around $55 million of shares will be purchased by entities controlled by Chairman and CEO Yang Lu. Adlai Nortye agreed to file a registration statement covering resale of the ADSs issued in the financing.
Adlai Nortye Ltd. received a Schedule 13G reporting that Unique Mark Ventures Limited and its parent Fine Process Limited beneficially own 5,750,790 Class A ordinary shares, equal to 6.14% of this class. The position relates to American Depositary Shares, each representing three Class A ordinary shares.
The shares are registered in the name of Unique Mark Ventures Limited, which is wholly owned by Fine Process Limited and, through intermediate entities, ultimately controlled by Industrial and Commercial Bank of China Limited, a PRC state-owned bank and public company. Voting and dispositive power over these shares is exercised on a shared basis, with no sole voting or dispositive power reported.
The 6.14% figure is calculated using 93,710,803 Class A ordinary shares issued and outstanding as of the company’s 2024 annual report, providing investors with an updated view of this institutional holder’s stake.
ANL Talent Limited reported beneficial ownership of 9,300,000 ordinary shares of Adlai Nortye Ltd., representing 7.75% of the company’s ordinary shares outstanding as of December 31, 2025. These shares have sole voting and dispositive power attributed to ANL Talent.
The shares are held through a trust structure for the benefit of certain Adlai Nortye employees under the company’s share incentive plan. ANL Talent is ultimately owned by Trident Trust Company (HK) Limited, which acts as trustee and must follow directions or prior written consent from an advisory committee currently comprising an authorized representative of the issuer, namely Xiao Zhang.
Adlai Nortye reported unaudited first half 2025 results showing a smaller loss and lower cash burn while advancing its oncology pipeline. Net loss for the six months ended June 30, 2025 narrowed to $18.3M from $27.7M a year earlier, as research and development expenses fell 41.4% to $15.2M and general and administrative costs declined to $4.1M. Net cash used in operating activities was $15.1M, compared with $28.4M in the prior-year period.
Cash and cash equivalents were $44.1M as of June 30, 2025, plus $18.2M of restricted cash, while shareholders’ equity stood at $7.9M. The company highlighted progress across multiple drug candidates: phase I for AN8025 is ongoing; AN4005 has moved into expansion cohorts with proof-of-concept data planned for 2026; AN0025’s phase II ARTEMIS study is under way; and first-in-human or IND-enabling steps for AN9025 and AN4035 are targeted around 2026.
Adlai Nortye Ltd. submitted a Form 6-K as a foreign private issuer for October 2025. The filing primarily provides materials for an upcoming extraordinary general meeting of shareholders, including a formal notice of the meeting and a proxy card for shareholders to use when voting.